Monitoring kidney function helps catch any decline early, particularly in people with existing kidney disease or risk factors
et al., NNMT regulates cellular metabolism through NAD and methyl donor balance, Nature Chemical Biology, 2013
Clinical Evidence on GLP-1/GIP Therapy and Fluid Balance The SURPASS clinical trials, which evaluated tirzepatide's safety and efficacy, did not identify water retention as a primary side effect
A: Yes, rare but serious side effects of Tirzepatide Subcutaneous Route include anxiety, bloating, blurred vision, change in vision, changes in behavior, chest tightness, chills, cold sweats, coma, confusion, constipation, cool, pale skin, cough, darkened urine, depression, dizziness, fast heartbeat, fever, increased hunger, indigestion, large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs, loss of appetite, nausea, nervousness, nightmares, pains in the stomach, side, or abdomen, possibly radiating to the back, puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue, seizures, shakiness, slurred speech, thoughts of harming oneself, and unusual tiredness or weakness
Retatrutide 20mg/3ml Peptide Pen is an advanced GLP-1, GIP, and glucagon receptor agonist research peptide formulated for studies focused on metabolic regulation, obesity management, and energy balance
Most of the trials were conducted in middle- and high-income countries, with little or no representation from regions such as Africa, Central America, and Southeast Asia
